First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent
Patwardhan RS, Rizvi ZA, Gota V, Checker R, Singh B
Published in Phytomedicine
Methodology
First-in-human safety, pharmacokinetic and pharmacodynamic trial of high-dose sodium copper chlorophyllin in healthy male subjects, with supporting in vitro and animal models
Key Findings
High-dose chlorophyllin was well tolerated with measurable systemic exposure and immunomodulatory pharmacodynamic effects; antiviral activity was shown in vitro and in animal models.
Conclusions
Chlorophyllin has a favourable safety profile at high doses and warrants controlled efficacy trials as an immunomodulatory agent.
Limitations
Healthy male volunteers only; no clinical efficacy endpoint in humans; antiviral claims rest on preclinical data.
Supplements Studied
A first-in-human clinical trial of high-dose CHL was conducted in healthy male subjects, and pharmacokinetics, pharmacodynamics, and safety were evaluated.
Study Details
Access Study
Disclosures
Funding
Institutional/government research funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.